PF-AtlasClinical Trials › NCT05157685

Evaluation of the Efficacy of Azithromycin in Idiopathic Purulent Oedematous Sinusitis in Adults

Azithromycin Oral Tablet · Phase 3

Registry ID
NCT05157685
Phase
Phase 3
Status
Recruiting
Drug / intervention
Azithromycin Oral Tablet
Sponsor
Centre Hospitalier Intercommunal Creteil
Start
2022-11-21
Enrollment
230
Locations
13

About this trial

Purulent Oedematous Sinusitis (POS) is a particular form of chronic rhinosinusitis observed in 2% of the general population. In spite of its heavy impact on the quality of life, There is no established recommendation for the treatment of primary POS. Long-term low-dose macrolides are currently proposed for these forms of chronic rhinosinusitis when conventional treatments (local corticosteroids, saline rinsing, iterative short courses of antibiotics targeted on pathogens, and surgical opening and drainage) have failed. This treatment with macrolides is currently applied off-label. This study aims to assess the efficacy of macrolides in POS. An extensive workup is fulfilled to exclude other forms of chronic rhinosinusitis (Th2 biased inflammatory diseases, allergic diseases) (allergy, nasosinusal polyposis) or those due to cystic fibrosis or immune deficiency.

View NCT05157685 on ClinicalTrials.gov →

Explore related

Medical disclaimer. This page summarizes public trial data for NCT05157685 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.